Table 3.

Enrolment, intervention, and assessment schedule

Study period
Time points	Enrolment Baseline	Allocation Baseline	Post allocation
			Baseline	Week 12	Week 24	Week 36	Week 48 (close out)
Enrolment
Eligibility screen	x
Informed consent	x
Allocation: Intervention arm (topical drugs and improved support) or non-intervention arm (topical drugs)		x
Topical drugs
Assessments:
Socio-demographics			x
Primary outcome:
LS-PGA			x	x	x	X	x
Secondary outcomes:
Rates of adherence:
Primary adherence (proportion of filled new prescriptions)							x
Secondary adherence (by proportion of consumed amount of prescribed medication and in a study-specific PRO questionnaire)							x
DLQI (PRO questionnaire)			x	x	x	X	x
EQ-5Da (PRO questionnaire)			x				x
Total cost of anti-psoriatic treatment			x				x

Abbreviation: DLQI Dermatology Life Quality Index, EQ-5D European Quality of life 5 Dimensions, LS-PGA Lattice-System Physician's Global Assessment, PRO patient-reported outcome

^aEQ-5D is collected for use in the health-economy analysis